MedTrace Logo

Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit

NCT00167960 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2007-03-15

No results posted yet for this study

Summary

To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)

Conditions

  • Gram-Positive Bacterial Infections

Interventions

DRUG

Piperacillin/tazobactam and other β-lactam/β-lactamase

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00167960 on ClinicalTrials.gov